title: Real-world utilization of ranibizumab in wet age-related macular degeneration patients from Canada.
authors.affiliation: University of Toronto, Toronto, Ont.
authors.forename: Robert
authors.initials: R
authors.lastname: Devenyi
authors.affiliation: University of British Columbia, Vancouver, B.C.
authors.forename: David
authors.initials: D
authors.lastname: Maberley
authors.affiliation: Western University, London, Ont.
authors.forename: Tom G
authors.initials: TG
authors.lastname: Sheidow
authors.affiliation: Hôpital St-Sacrement, Quebec, Que.
authors.forename: Eric
authors.initials: E
authors.lastname: Tourville
authors.affiliation: Bayer Inc., Mississauga, Ont.
authors.forename: Lynne
authors.initials: L
authors.lastname: Brunck
authors.affiliation: University of Toronto, Toronto, Ont.. Electronic address: bergera@smh.ca.
authors.forename: Alan R
authors.initials: AR
authors.lastname: Berger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002170:Canada; D005062:European Union; D005260:Female; D006801:Humans; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D000069579:Ranibizumab / Q000627:therapeutic use*; D019233:Retreatment; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab